Apath is offering the HCV Replicon System for non-exclusive licensing to the pharmaceutical industry for their in-house antiviral therapeutic and antibody development programs. Along with the functioning cell lines, Apath is offering cDNA of the most advanced replicons for licensees to develop their own cell lines.
The license also provides a non-exclusive right to make and use any HCV replicon under Apath's patent estate. The patent estate includes several patents which have claims covering the use of HCV replicons. The terms of the offer are available for review under a confidential disclosure agreement between Apath and the receiving company.
The HCV 3’NTR Patent Estate was developed by Dr. Rice while he was a professor at Washington University. This technology encompasses a global patent estate covering the identification and use of the 3’NTR Technology, the global estate covering the invention of the Functional DNA Clone Technology and the global patent estate covering the invention of the HCV Variants Technology.
Apath is offering the Highly Permissive Cell Line Technology for non-exclusive licensing to the pharmaceutical industry for their in-house antiviral therapeutic and antibody development programs. This technology encompasses a global patent estate covering the industry standard platform for generating validated replicon and high titer full virus systems. Additionally, Apath offers Huh7.5 cell line derivatives (Huh7.5.1 cells) developed at The Scripps Institute by Dr. Frank Chisari.
Apath is offering the HCV Full Virus Life Cycle Technology for non-exclusive licensing to the pharmaceutical industry for in-house antiviral therapeutic and antibody development programs. The HCVcc Patent Estate encompasses four industry leading institutions, Toray Industries, LTD., The Rockefeller University, The Public Health Service and Tectra, The Capital Region of Denmark. These technologies encompass a global patent estate covering the development of the JFH-1 virus and JFH-1 chimeric viral infection systems.
In addition, Apath is offering to license rights to the 3' NTR region of the HCV genome as a diagnostic target. Apath has non-exclusively licensed rights to the 3' NTR for diagnostic applications to Luminex Corporation. Please contact Robert Roth for additional information and licensing opportunities related to HCV diagnostics.
Please contact us for a description of Intellectual Property Rights Offered by Apath.
Please contact us for a description of Tangible Property Offered by Apath.
The intellectual property environment for HCV research is complex and continually evolving. For these reasons, Apath cannot provide any guaranty or warranty of non-infringement of other third-party patents in this area.